Daily Archives: 2011/07/14
Update on Pediatric Vision Scanner That Offers Breakthrough Method of Detecting Any Form of Amblyopia in Small Children
Several months ago we reported on a new device, called the Pediatric Vision Scanner, which uses a laser beam to measure the alignment of children’s eyes. Now we bring you newly released details on clinical testing of the device.
New Human Embryonic Stem Cell Study For Dry AMD And Stargardt’s Macular Dystrophy
Two patients have been treated using RPE (retinal pigment epithelial) cells derived from hESCs (human embryonic stem cells) in two Phase 1/2 clinical trials for dry age-related macular degeneration and Stargardt's macular dystrophy, Advanced Cell Technology Inc. has announced.
Transcend Medical Closes $51M Series B Financing
Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced the closure of its second tranche, bringing the total of Series B to $51M.
Histopathologic Complications Seen Post-Intra-Arterial Chemo
Though retinoblastoma can be controlled by intra-arterial chemotherapy (IAC), histopathology demonstrates that ocular complications, including thromboembolic events, can occur, according to a study published online July 11 in the Archives of Ophthalmology.
ACT Announces First Patients Undergo Embryonic Stem Cell Transplantation Treatment For Stargardt’s Disease And Macular Degeneration At UCLA’s Jules Stein Eye Institute
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were treated Tuesday (July 12) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute. Robert Lanza, M.D., chief scientific officer of ACT, attended the procedures. Both patients successfully underwent the outpatient transplantation surgeries and are recovering uneventfully.
Transcend Medical Closes $51M Series B Financing
Transcend Medical, Inc., an ophthalmic device
company dedicated to developing minimally invasive glaucoma therapies,
announced the closure of its second tranche, bringing the total of Series B to $51M.
Introduction to the Reichert Reflex UBM and Clearscan(R) ultrasound probe cover
Learn how the Reichert Reflex Ultrasound Biomicroscope, combined with innovative ClearScan (R) probe covers, enables operators to easily image the anterior and posterior segments of the eye.
Subscribe
